Drug

Biosimilar Boon for Europe’s Payers as Humira Price Falls

  • November, 18 2018
  • 661

AbbVie is being hit harder than expected by the October 2018 arrival in Europe of biosimilar versions of Humira (adalimumab). Europe’s payers were better prepared than ever to take full advantage of the competition, helping push the price of this top-sell

Company

Biopharma companies have the cash and are ready to deal

  • October, 25 2018
  • 298

PharmaVitae M&A Outlook 2018 predicts that merger and acquisition (M&A) activity will remain robust at least through the rest of 2018, due in large part to a favorable tax environment. The lower tax rate, coupled with the ability to “repatriate” u

Related Videos
Oliver Spray Analyst
Oliver Spray Analyst

M&A Outlook for 2018

Amanda Mucklus Analyst
Amanda Mucklus Analyst

Diversification Strategy

Pharma Intelligence
Pharma Intelligence

Biosimilars Battlegrounds

Pharma Intelligence
Pharma Intelligence

Q4 2018 Outlook Webinar